Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder cancer because it offers the strongest chance of cure when the disease has ...

SAN FRANCISCO -- Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a "promising" clinical complete response rate, as well as bladder preservation, in nearly 40% of ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...

New research identifies distinct urinary metabolites linked to bladder cancer and recurrence, raising hope for non-invasive ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...